Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

PRADAXA 110 MG

DABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE MESILATE) : 110 MG · DIN 02312441 · BOEHRINGER INGELHEIM (CANADA) LTD LTEE

Health Canada status: MARKETED

What is PRADAXA?

PRADAXA 110 MG contains DABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE MESILATE) : 110 MG. It is listed in the Health Canada Drug Product Database under DIN 02312441, held by BOEHRINGER INGELHEIM (CANADA) LTD LTEE, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 03-Jul-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is PRADAXA used for?

PRADAXA (dabigatran etexilate) is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement (THR) or total knee replacement (TKR) surgery; treatment of venous thromboembolism events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE; prevention of stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation is appropriate.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02312441
Brand namePRADAXA
Generic / active ingredientDABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE MESILATE) : 110 MG
ManufacturerBOEHRINGER INGELHEIM (CANADA) LTD LTEE
Strength110 MG
Dosage formCAPSULE
Route of administrationORAL
SchedulePrescription
ATC codeB01AE07 DABIGATRAN ETEXILATE
AHFS class20:12.04.12
BiosimilarNo
Health Canada statusMARKETED
Status date03-Jul-2008
Original market date2008-07-03 00:00:00

How is it stored and handled?

null

How is it supplied?

null

What can be used instead?

Other Canadian products sharing ATC code B01AE07 DABIGATRAN ETEXILATE. 5 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
APO-DABIGATRAN110 MGCAPSULEAPOTEX INCMARKETEDDIN 02468905
APO-DABIGATRAN150 MGCAPSULEAPOTEX INCMARKETEDDIN 02468913
APO-DABIGATRAN75 MGCAPSULEAPOTEX INCMARKETEDDIN 02468891
PRADAXA150 MGCAPSULEBOEHRINGER INGELHEIM (CANADA) LTD LTEEMARKETEDDIN 02358808
PRADAXA75 MGCAPSULEBOEHRINGER INGELHEIM (CANADA) LTD LTEECANCELLED POST MARKETDIN 02312433
TEVA-DABIGATRAN150 MGCAPSULETEVA CANADA LIMITEDCANCELLED PRE MARKETDIN 02463466
TEVA-DABIGATRAN75 MGCAPSULETEVA CANADA LIMITEDCANCELLED PRE MARKETDIN 02463458

Who else supplies DABIGATRAN ETEXILATE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. DABIGATRAN ETEXILATE appears in 448 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for PRADAXA

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for PRADAXA

Health Canada Drug Product Database (DPD), DIN 02312441. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.